Kenvue Inc. $KVUE Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 5.5% during the second quarter, HoldingsChannel.com reports. The fund owned 225,242 shares of the company’s stock after selling 13,168 shares during the period. Nisa Investment Advisors LLC’s holdings in Kenvue were worth $4,714,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the business. Wealthfront Advisers LLC increased its holdings in shares of Kenvue by 200.3% in the 2nd quarter. Wealthfront Advisers LLC now owns 162,853 shares of the company’s stock valued at $3,409,000 after acquiring an additional 108,620 shares during the period. Saybrook Capital NC increased its holdings in shares of Kenvue by 2.2% in the 2nd quarter. Saybrook Capital NC now owns 360,049 shares of the company’s stock valued at $7,536,000 after acquiring an additional 7,669 shares during the period. MQS Management LLC acquired a new position in shares of Kenvue in the 2nd quarter valued at $301,000. B & T Capital Management DBA Alpha Capital Management increased its holdings in shares of Kenvue by 3.0% in the 2nd quarter. B & T Capital Management DBA Alpha Capital Management now owns 213,447 shares of the company’s stock valued at $4,467,000 after acquiring an additional 6,257 shares during the period. Finally, AG2R LA Mondiale Gestion D Actifs increased its holdings in shares of Kenvue by 4.7% in the 2nd quarter. AG2R LA Mondiale Gestion D Actifs now owns 75,683 shares of the company’s stock valued at $1,584,000 after acquiring an additional 3,427 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. JPMorgan Chase & Co. cut their target price on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Canaccord Genuity Group dropped their price objective on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Jefferies Financial Group dropped their price objective on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Monday. Citigroup dropped their price objective on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a research note on Thursday, October 9th. Finally, Barclays dropped their price objective on shares of Kenvue from $20.00 to $17.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Kenvue has an average rating of “Hold” and an average price target of $20.90.

Kenvue Price Performance

Shares of NYSE KVUE opened at $14.49 on Wednesday. The firm has a market capitalization of $27.80 billion, a P/E ratio of 19.57, a PEG ratio of 2.18 and a beta of 0.72. Kenvue Inc. has a one year low of $14.05 and a one year high of $25.17. The company’s fifty day moving average is $17.64 and its two-hundred day moving average is $20.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, August 7th. The company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.28 by $0.01. The company had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s revenue was down 4.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.